Retatrutide in Jamaica: an unapproved triple agonist and the law

Retatrutide is the next name after semaglutide and tirzepatide that patients bring to Jamaican consulting rooms. It is a single peptide that activates three receptors, and its trial results have been striking. It is also still investigational and unlicensed²⁵, which in Jamaica has direct legal consequences. This article sets out the evidence, the enforcement record abroad, and what Jamaican law says. For the drugs that are on the market, see our article on GLP-1 access in Jamaica.

What retatrutide is

Lilly's medical information page describes retatrutide as a "novel synthetic molecule" that is an agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), and as an "investigational molecule and is not currently approved in the United States"⁵. Semaglutide acts on one of those receptors and tirzepatide on two.

The trial evidence so far

The first full publication was a phase 2 trial in the New England Journal of Medicine with 338 adults with obesity¹. At 48 weeks, mean weight change was -24.2% on the highest dose versus -2.1% on placebo, and 83% of people on the highest dose lost at least 15% of body weight¹. Gastrointestinal events were the most common side effects and were dose-related, and heart rate rose in a dose-dependent way, peaking at 24 weeks¹.

Phase 3 results are arriving as topline announcements, not yet peer-reviewed papers. In TRIUMPH-4, in adults with obesity or overweight and knee osteoarthritis, the 12 mg arm lost 28.7% of body weight at 68 weeks, versus 2.1% on placebo, with a 75.8% reduction in WOMAC knee pain³. In TRIUMPH-1, with 2,339 participants, weight loss at 80 weeks was 17.6%, 23.7% and 25.0% across the three doses versus 3.9% on placebo².

The safety picture is still incomplete

In TRIUMPH-1, the most common adverse effects on the highest dose were nausea (42.4%), diarrhoea (32.0%), constipation (26.1%) and vomiting (25.3%); dysesthesia and urinary tract infections were reported in about one in ten participants on the highest doses². Discontinuation for adverse events was 4.1%, 6.9% and 11.3% by dose versus 4.9% on placebo². In TRIUMPH-4, about 18% stopped the top dose because of side effects, versus 4% on placebo³. Hannah Beba, clinical lead for obesity at the West Yorkshire Health and Care Partnership, told The Pharmaceutical Journal that retatrutide "remains investigational and unlicensed, and the full safety data deserve careful scrutiny once peer-reviewed"².

The grey market abroad

Demand has run ahead of approval. The US consumer group Public Citizen reported in June 2026 that the FDA had sent 14 warning letters to companies selling retatrutide since 2024, that eight of those sellers were still selling it as of May 2026, and that 14 hospitalizations connected to retatrutide had been reported in the FDA's adverse event system⁴. Peter Whoriskey, research director of its Health Research Group, said: "The era of snake oil and quack medicine is back"⁴.

One FDA warning letter, sent to a California seller in March 2026, named retatrutide and said that "these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act"⁷. The FDA based its view on the seller's own claims that the product "[D]emonstrated significant potential for reducing body weight, improving glucose handling, and enhancing lipid metabolism", regardless of the labels the seller used⁷. Independent test purchases of semaglutide from illegal online pharmacies show what such products can contain: purity of 7.7% to 14.37% and endotoxin in every vial⁸.

What Jamaican law says

Jamaica's Food and Drugs Regulations, 1975 are clear. Regulation 40(1) says "A person shall not sell, manufacture, import or distribute a drug unless" it "has been registered with the Ministry of Health"⁶. Regulation 43(1) adds that "A person shall not import a drug unless he has applied for and obtained permission to do so from the Minister"⁶. An investigational drug that has not been registered falls squarely under these rules. In 2025 the Pharmacy Council of Jamaica's chair, Dr Ernestine Watson, warned that Ozempic was being advertised on Instagram and offered locally without the required approvals, and that sellers' numbers vanish "after the second call"; the Jamaica Information Service described such drugs as "unregistered or unapproved for distribution in Jamaica"⁹.

Practical points for Jamaican physicians

• A patient using retatrutide is using a product that was not lawfully sold or imported under regulations 40 and 43⁶, with unknown content⁸.
• Ask about it directly. Heart rate, gastrointestinal effects and dysesthesia were among the effects seen in trials¹².
• Report adverse events and suspected falsified products to the Ministry's PharmWatch scheme, which asks for reports "even if" causality is uncertain¹⁰; see our article on PharmWatch and GLP-1 side effects.
• Obesity in Jamaica is common: 28.9% of rural adults in JHLS III data¹¹. Approved GLP-1 options exist, and WHO's 2025 guideline places them inside comprehensive care¹².